Blood marker study aims to predict COVID-19 severity in transplant patients

NCT ID NCT04369456

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Apr 02, 2026 · Last updated May 20, 2026 · Updated 5 times

Summary

This study looked at whether a simple blood test could predict which kidney transplant patients with mild-to-moderate COVID-19 would get worse. Researchers measured a protein called IL-6 in blood samples after stimulation. The goal was to find early warning signs to guide treatment and prevent severe outcomes like needing intensive care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONAVIRUS INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

APHM

Marseille, 13000, France
APHP

Paris, 75000, France
Lyon Univerity Hospital

Lyon, 69000, France
Montpellier University Hospital

Montpellier, 34000, France
Saint Etienne University Hospital

Saint-Etienne, 42000, France
Strasbourg Univeristy Hospital

Strasbourg, 67000, France
University Nice Hospital

Nice, 06000, France

Conditions

Explore the condition pages connected to this study.

CORONAVIRUS INFECTION KIDNEY TRANSPLANT; COMPLICATIONS KIDNEY TRANSPLANT; COMPLICATIONS